Stoke Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Great. All right. So I think we're ready to get started. Great. All right. Well, it is my pleasure to introduce Ian Smith, CEO; and Jason Hoitt, Chief Patient Officer of Stoke Therapeutics. My name is Kevin Strang, I'm one of the biotech analysts here at Goldman Sachs. Welcome.
Thank you, Kevin.
Questions & Answers
And -- I guess we'll just start getting right into a question for you, Ian. What were your priorities when you took on the CEO role at Stoke? And can you sort of provide a mark-to-market on your progress against those priorities and what you're focusing on from here?
Yes. So First of all, thank you for everybody joining us on the webcast and those that are in the room with us today. Just as stepping back, I -- I've been on the board of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
